initi coverag
initi overweight believ hiv busi sustain
invest summari initi coverag
outperform rate pt believ base busi
stabil expect pipelin remain rel low think earn
bottom hcv becom predict estim trade
multipl next year vs peer somewhat
stabl earn think investor look pipelin diversifi
drive growth think compani move period
late-stag pipelin readout report focus work franchis
key get thesi right hiv nash inflamm
speak head
believ gild hiv busi sustain next year even
gener competitor enter model base case model
growth compound-annual-growth-rate hiv busi check
think biktarvi becom one gilead biggest hiv launch peak potenti
innov key maintain competit
advantag hiv gener remain biggest risk gild long-term hiv
busi sourc investor debat taf dolutegravir regimen lose
exclus start model gener eros increas post
see import readout late-stag pipelin next month
allow diversifi franchis time taf regimen
begin lose exclus still think market doesnt give credit
late stage pipelin think filgotinib grow meaning product
year think ra data look strong rel competitor
concern preclin find test sinc
preclin minim histolog find test two speci find
found human nash estim peak potenti nash
franchis readout cautious optimist
think meaning player space compani mani
differ target beyond combin
new leadership signific cash posit two key posit swing
factor next month thesi believ air
evolut within manag think new leadership could definit
chang investor think gilead time addit gilead still
larg cash balanc could deploy partnership think
swing factor like tailwind gilead
disclosur section may found page
initi coverag gilead
believ hiv busi sustain
gilead global biopharmaceut compani major base busi
revenu base infecti diseas pipelin evolv inflamm oncolog
nash compani headquart foster citi california
thesi summari
gild base busi stabil hcv hit steadi state new hiv
biktarvi launch drive growth believ gild hiv franchis
sustain long-term also believ late-
stage pipelin readout next month could drive upsid
gilead signific cash allow flexibl strateg grow
revenu well two key downsid risk valuat would
hiv busi slow late-stag pipelin failur
rate share overweight price
use probability-adjust dcf analysi model cash flow
assum discount rate termin growth assumpt
catalyst could drive upside/downsid month
hiv busi sustain next year gener
believ gild brand franchis differenti gener
potenti gild nash franchis
cautious optimist program interest
combin studi read also believ could acquir asset
complementari
gilead build new empir oncolog post kite
posit surpris yescarta launch far want know
gilead specif clinic develop plan car-t
earn trough year
believ earn nearli bottom
gilead relev eventgild druggild go-forward bcma oncolog cell finch ra datafilgotinib inflamm finch ra datafilgotinib inflamm prep combo data gilead comp compsmarket cap price-to-earnings factset price gilead sciences- oper metric perform
valuat use probability-adjust dcf analysi valu gilead share assum discount rate model revenu
assum termin valu roughli gilead valuat base termin valu lower peer due
base busi mostli small molecul
compani report factset research cantor fitzgerald research price
inc gild-u recent outstand cap valu day interest cover current market valu mm outth vanguard group fund research manag co global fund manag manag research invest row price associ capit manag rate comp estim vs consensu
exhibit quarterli estim vs cantor fitzgerald factsetexhibit annual estim vs cantor fitzgerald factsetexhibit gilead comp compspricemarket cap ev sale ep price-to-earnings factset gilead thesi valuat stabil pipelin continu build momentum
expect fairli low around pipelin
launch overweight rate price target
think gilead hiv busi stabl grow come year
believ gilead new hiv product franchis taf drive growth legaci
busi erod patent expir
bullish around biktarvi launch global basi
think expect remain modest part gild pipelin includ car-t nash
think compani well capit cash make invest
pipelin next month curiou new manag chang gild
interest prioriti
gilead overview domin hiv player lower exposur hcv increas exposur
pipelin
gilead base busi mostli focus treatment hiv
gilead domin market share hiv therapi us europ current sell
hepat hcv franchis becom much smaller portion total revenu
think busi stabil
yescarta car-t launch compani major foray oncolog
exhibit cantor estim gilead pipelin revenu cantor fitzgerald expansionexhibit gilead base busi break-out franchisesourc cantor fitzgerald franchisehcv franchiseyescartaoth revenu reflect gild past present futur evolut air foster citi
gilead known develop therapi hepat infecti diseas
opportun matur compani move toward new therapeut modal
exhibit cantor reflect stand storywher come past month gradual stabil hcv busi enter pan-genotyp regimen august kite acquisit along compani support new therapeut modal focu compani view hiv stabl biktarvi launch remain importantwher current focu biktarvi focu yescarta launch develop car-t question remain deploy hcv busi fairli stabl new regimen gain share initiallywher go new manag growth yescarta biktarvi late-stag pipelin emerg opportunti mid-stag sourc cantor fitzgerald research septemb
investor gilead debat view
debat high level view
gilead earn stabil forward multipl real multipl
busi stabl comfort trough multipl truli
case mani fit start call ep bottom
believ earn stabil point
biktarvi new competit hiv affect sustain hiv revenu
degre biktarvi launch rob peter pay paul mean
erod current hiv franchis
therefor care doubl count
gsk also new hiv therapi develop dont view
buy kite good idea bad idea
think investor still cautiou gilead foray cell therapi
question remain much credit assign pipelin
estim yescarta revenu light novarti nv cover
estim cell therapi pipelin revenu probability-adjust
debat high level view
gilead evolv light manag chang
recent manag chang transit ceo veteran john milligan
think go
gilead buy question never get old
gilead cash june
still think compani deal size lower
focus due dilig get right next month
major report focus due dilig topic
understand pipelin develop cell therapi
gilead notabl quiet broadli frame key catalyst
learn due dilig
continu strength hiv busi
gilead hiv busi key potenti earn growth would help drive upsid
learn due dilig
estim biktarvi sale vs consensu
yescarta launch emerg competit dlbcl
think investor still cautiou gilead foray cell therapi
estim yescarta revenu vs consensu light
filgotinib posit long-term rel biosimilar
proprietari report
highlight launch
hiv detail analysi understand hiv trend care model estim key
thesi done variou type check model product sale region legaci
new product
didnt want valuat inflat potenti double-count could
happen biktarvi launch patient switch regimen
analysi therapeut nash market analysi gild current product portfolio
first data expect
quick competit analysi around pipelin filgotinib
spoke gild head key take
spent time manag help us think upcom late stage pipelin
filgotinib- ask recent data find test get lot attent
manag remain encourag recent readout
get subgroup analysi like prior biolog use think find
manag note find test histolog find end
tox studi lab find speci rat dog one
sensit
selonsertib- ask underpin confid
human upregul proport amount fibrosi
human nash complet block target
complet target engag shown biopsi
dose depend effect dose alt blood fibrosi resolut nash
block hepat stellat cell lay collagen
studi look advanc cirrhosi liver worst
state end road
spoke gild head key take
spent time manag help us think upcom late-stag pipelin
hiv innovation- new front
think innov way includ long-act product
could use resist diseas front-lin prep prophylaxi treatment
risk exposur hiv
primat long-act half-lif primat day
pain-fre inject key proposit patient
car-t cell therapi strategi pay attent
compani activ deal space past month
cell design lab may util solid tumor
file ind hpv protein serotyp head neck cervic cancer
think compani excit sangamo collabor allow
gene edit cell
big question next ceo
mani senior execut transit gilead pave way new leadership team build
success prior manag
gilead manag one tenur group execut work togeth
coverag univers
past year seen mani posit transit
exhibit chang manag
evp cso
develop
stepping-down end
promot april
leav end
join august
svp head ww
chairman board
think upsid next month driven pipelin
overview gilead catalyst focus next month
cautiou readout nash see mani nash therapi emerg
landscap gilead could acquir matur
phase data
phase data
phase combo data
expect gild hiv busi grow initi phase gener earli
hiv remain key focu gilead share
notabl much signific eros legaci product start compar
consensu
think conserv appropri exact gener current product
estim higher dcf would higher
exhibit hiv busi growth cantor vs consensu factset cantor hivproductscantornew hivproductsconsensustot hiv -cantortot hiv -consensu chang sinc prior coverag bullish next month
reason
previous late thought share would trade sideway earn bottom chang
earn nearli bottom
share pull back significantli gilead stock vs month ago
nbi current forward multipl vs jan
get closer pipelin readout begin felt timelin
still far away
partnership enhanc cell therapi busi think compani well
capit make invest pipelin next month
valuat use probability-adjust dcf analysi
month price target
assign termin valu dcf gilead lower percentag total npv
compar peer howev
cantor biotech discount analysisalethia base work present valu termin growth npv termin risk import view sustain hiv franchis
risk thesi hiv base busi pipelin prudent deploy capit
biktarvi launch slow due competit
merck gsk program underway howev continu innov hiv
long-term post greater hiv eros taf regimen product model
big compon thesi point gild hiv busi remain fairli stabl
yescarta launch slow car-t competitor enter
novarti current market compet discuss
toxic benign
cell therapi doesnt grow centerpiec franchis futur
though compani diversifi pipelin project big part invest around
cell therapi hematolog oncolog place compani less
experi base histori
non cell-therapi pipelin lead commerci revenu beyond
cell therapi non-cel therapi pipelin think investor
comfort give termin valu credit
particular think inflamm nash howev think
cash gilead signific flexibl acquir
gild hiv franchise- crown jewel
erod busi
innov launch
conclus around gilead hiv business- remain posit long-term sustain
perhap past prologu gilead hiv though think still sourc investor debat
gilead use innov understand market develop therapi move
needl treatment hiv patient
one point evid guidelin continu adopt regimen rapidli
singl tablet taf integras inhibitor exampl innov
hiv gener new brand competit remain threat think
current expect next year look achiev
think biktarvi drive global growth hiv busi legaci product start go
gener us global
hiv new start market continu grow even though mani new therapi gilead take
signific share new market everi year patient stay drug longer
think gilead continu innov hiv evidenc new earli stage work though
note gilead made bar high
new innov mostli greater conveni complianc develop drug
resist patient current care
bullish around near-term hiv busi
gener definit taken share new brand product seen uptak
think gener remain key area focu investor
gener beyond expect well
exhibit hiv consider thesi
think new integras product seen signific uptak naiv
also switch patient
think risk like signific earliest integras inhibitor go
gener late
think biktarvi best-in-class oral competitor look
differ type administr frequenc dose
guidelin continu favor better hiv regimen recommend
guidelin payer pressur
integras repres step forward treatment adopt rapidli
think payer reimburs guidelin support ultim
prophylaxi treatment hiv prep
near-term provid boost truvada sale descovi current
develop would favor toler prep patient
cure think gilead abl maintain hiv lead
gilead work variou hiv pipelin asset long dose frequenc
continu innov space
background gilead proven life cycl manag abil hiv view give us
basi confid continu grow key brand product
new taf-bas regimen enter market launch genvoya gilead
domin hiv year
gilead abl understand commerci physician patient would like
innov efficaci toler
creat toler agent allow re-model franchis new version
current product like truvada viread stribild
integras inhibitor like genvoya biktarvi new singl tablet therapi choic
fewer drug-drug interact
taf base regimen
product
exhibit gilead hiv approvalsexhibit exclus loss year gilead drugsgilead therapyapprov yeargilead therapyu patent exclus lossviread acquiredemtriva acquiredemtriva extens gileadsourc gilead septemb
year gilead abl shift major commerci market toward new
hiv therapi commonli call descovi taf-bas
rememb skeptic around whether toler taf regimen realli meant anyth
atripla truvada lose exclus us alreadi lost exclus ex-u
gilead develop descovi taf truvada base regimen favor toler
bone kidney sinc hiv popul age live hiv chronic rather die
hiv nowaday
addit newer product give gilead new product life cycl hiv
higher biktarvi consensu us slightli lower europ
compound-annual-growth-rate gild hiv busi
moder growth start around product matur model modest
annual share growth throughout
us model gradual increas discount start
see three key hiv gener wave gilead maneuv order achiev sustain
wave earli legaci single-tablet product lose exclus
take new taf regimen alreadi driven signific shift less
concern growth cycl
take think risk also believ integras inhibitor
prefer class guidelin
wave late first integras inhibitor gsk cover lose exclus
take dont model cliff point busi deceler
exhibit gener hiv wave view
exhibit gener hiv wave descovi comp matter till elig patent term extensionssourc compani data gilead scienc teens- earli beyond expect trend remain taf regimen take legaci product share
favor trend sinc atripla truvada lose exclus us alreadi lost exclus ex-u
atripla truvada growth slow respect next year vs new taf
product growth increas compound-annual-growth-rate next year
truvada benefit prep henc make much stabl thought
light taf-bas regimen enter market
model sale atripla truvada lose exclus post us
exhibit legaci hiv product eros cantor fitzgerald research compani atriplau truvadaexhibit taf hiv product growth cantor fitzgerald research compani genvoyau biktarvyu descovyu odefsey think look european gener trend atripla truvada give us comfort
around happen us earli
gener definit taken share europ new brand product seen uptak
think look gener like atripla truvada affect gild eu busi
instruct think us trend
thought greater risk around gener europ price sensit
find notabl brand product grow gener like atripla truvada
project gild hiv eu busi actual grow earli due taf
exhibit eu hiv annual revenu cantor estimatessourc cantor fitzgerald breakdown eu revenu new taf product legaci productssourc cantor fitzgerald tdf revenueseu taf revenu cost-sensit eu countri fairli cautiou adopt gener
sinc gener like atripla truvada becam gener eu think trend give
context us trend gener could hit market
countri still reimburs brand single-tablet regimen even gener
think spain franc two larger volum consum hiv med still mostli use brand
expect biktarvi see uptak europ spite gener clearli suggest
major countri shift gener
speak gilead uk like sensit cost also consum least
hiv volum
exhibit atripla gener eros ex-ussourc cantor fitzgerald research first order erosionsal million atripla roweros y/i declin exhibit atripla gener eros ex-ussourc cantor fitzgerald research first order erosionsal million truvada roweros y/i declin taf product drive growth next year think remain fairli
stabl mid
use bloomberg consensu caution outer year estim consensu vari great
overal near-term estim line consensu
lower consensu assum legaci product basic go
zero patent end us exampl atripla truvada
consensu estim model sale product post exclus
exhibit global hiv revenu cantor vs consensu cantor fitzgerald research bloomberg hiv cantortotal- hiv consensu broken estim legaci new product hiv
use bloomberg consensu caution outer year estim consensu vari great
consensu project per year legaci sale post wherea mostli
gone base case
exhibit us hiv revenu legaci vs new consensu cantor fitzgerald tdfu tafexhibit us hiv revenu legaci vs new tdfglobal taf base case model gener lower total hiv share
hiv us eu build
tri factor risk gilead control less market drug go
exhibit cantor estim patient brand hiv drug cantor fitzgerald patient producteu patient productexhibit cantor estim patient brand hiv drug cantor fitzgerald us brand market share eu brand market share septemb
believ new hiv competit manag gsk merck
anoth near-term threat hiv brand competitor continu innov well
gsk juluca market anoth two-drug combo dolutegravir submit
merck develop nnrti doravirin better resist physician
check prefer still integras inhibitor
safeti concern emerg dolutegravir may limit commerci potenti
combin
exhibit competit product timelin hiv
exhibit competit product timelin hivdrugclasscompanyl stage studiesexpect data approvaldoravirin dor nnrtimerckdrive-forwardapproveddoravirine/lamivudine/tdfnnrti rilpavirin juluca ii nnrtigsk/viivsword also see singl sail spring flamingo ariaapproveddolutegravir lamivudin ii nrtigsk/viivgemini also see tangosubmit cabotegravir rilpivirin long act ii nnrtigsk/viivflair atla also see regulatori submissionsourc compani data cantor fitzgerald research septemb
side effect emerg dolutegravir mention check
compar safeti integras inhibitor
seriou case neural tube birth defect report babi born women treat
dolutegravir report fda
preliminari result on-going observ studi botswana issu
patient look get pregnant
present sabranski also suggest higher rate side effect dolutegravir
compar integras women older patient
still rel small rate higher integras
elvitegravir integras higher renal gi rate dolutegravir studi
exhibit observ studi comparison integras inhibitor
gilead keep innov tri creat option patient hiv therapi
year innov also help life cycl manag
roughli american know hiv therapi creat
opportun grow market well
greater conveni low volum pain-fre inject could potenti
gilead cantor fitzgerald research
potenti activ resist
potenti longer act option
broadli neutral antibodi
would part hiv erad
competit dlbcl
innov fairli crowd space
conclus around gilead pipeline- nash car-t like show-m stori
key swing factor remain gilead continu deploy cash
selonsertib data encourag fibrosi though still see risk
studi prefer combin studi grow long-term nash franchis
nash clear fit gilead franchis would expect pipelin asset
attract gilead may deal
posit filgotinib see data patient respond
safeti remain key factor especi market mani jak inhibitor
think car-t axi-cel yescarta similar efficaci car-t
think investor may give gilead credit strategi clear
hematolog nash inflamm biggest opportun pipelin
exclud pipelin sale valuat dcf would
model proof-of-concept opportun filgotinib
model sale gilead nash franchis single-ag combo opportun
biggest portion pipelin revenu car-t come dlbcl
exhibit gilead pipelin cantor estimatessourc cantor fitzgerald franchiseinflamm franchisecel therapi franchis nash focu broadli three main patholog associ nash
patient usual start fatti liver progress nash includ inflamm
scar last stage typic cirrhosi
patient nash classifi stage
drug develop typic target lipid metabol inflamm
gilead build portfolio nash asset led inhibitor selonsertib
gilead drug target three potenti mechan nash
selonsertib current studi
gilead fxr combin studi
exhibit mechan relat nashsourc gilead compani present septemb
expect data selonsertib studi
selonsertib novel kinas approach
first-in-class molecul inhibit apoptosi signal regul kinas signal
promot inflamm liver fibrosi set oxid stress also
believ play role progress nash
stellar program underway studi fibrosi
fibrosi read
exhibit studi design selonsertib program call stellar
placebo
placebo
proport patient achiev stage improv fibrosi
proport patient achiev stage improv fibrosi
accord nash crn without worsen fibrosi
accord nash crn without worsen fibrosi
event free surviv week assess time first clinic event
patient progress cirrhosi nash resolut greater equal
event free surviv week assess time first clinic event
patient progress cirrhosi nash resolut greater
stage improv w/o worsen nash
equal stage improv w/o worsen nash
inclus exclus
inclus biopsi accord nash crn classif central reader
exclus child pugh score meld score
inclus biopsi accord nash crn classif central reader
read cirrhosi alt uln creatatin clearanc
less equal
exclus child pugh score meld score unless due
proof-of-concept present simtuzumab control
fibrosi impact view strongest point evid present aasld
data aasld show proof-of-concept week studi liver biopsi
multi arm studi cohort combin simtuzumab
simtuzumab antibodi fail nash patient year
selonsertib arm ad benefit ad top
simtizumab fibrosi improv progress fibrosi
wasnt distinct differ chang reduct nafld activ score
exhibit fibrosi respons combin phase gilead single-ag show activ better combin dose
analysi supplement analysi publish data
selonsertib show dose depend impact fibrosi improv
group
exhibit anoth data cut selonsertib studi fibrosi liver fat
patient fibrosi
patient progress
mri-pdff chang
patient reduct
mre chang baselin
patient reduct
chang seen na score mechan action would suggest greater effect
fibrosi impact view strongest point evid present aasld
wasnt distinct differ chang reduct nafld activ score
note studi look na score usual year treatment durat
base work would expect inhibit lower inflamm
notabl safeti find
exhibit na score chang selonsertib studysourc gilead cautious optimist head stellar readouts- small phase fibrot
effect seen earli anoth studi
data present european hematolog meet
studi week rel short studi assess biopsi relat measur
combo studi look liver lab marker fibrosi
one interest find selonsertib didnt show effect mri-pdff liver fat
inhibitor fxr alon show better reduct
exhibit data liver fat fibrosi studysourc gilead septemb
gilead larger studi nash combin studi underway expect data
fibrosi impact view strongest point evid present aasld
get interim data includ biomark
would like get primari endpoint efficaci data around fibrosi chang biopsi
least earli project
monotherapi /selonsertib combo look interest phase
exhibit studi variou gilead combinationssourc gilead septemb
watch safeti profil combin approach
safeti data small studi present european liver meet
although small number dont see anyth notabl yet
acc/sel combin one person account mani advers event
event grade
exhibit safeti event seen variou fxr combinationssourc gilead nash estim fibrosi stage probability-adjust basi
peak unadjust estim
model sale
assum probabl success unadjust revenu base case
success would first nash product selonsertib
exhibit nash franchis sale cantor estimatessourc cantor fitzgerald nash franchis nash franchis sale septemb
oral ra market grow crowd differenti safeti key focu
mani biolog market like humira enbrel
increas number oral jak inhibitor enter market
jak market develop includ xeljanz olumi
mani jak includ filgotinib develop
exhibit competitor filgotinib develop
oral jak inhibitor develop chronic indic
ex vivo comparison suggest activ addit
collabor opt
gilead econom filgotinib especi us make import
us pay glpg cover royalti ex-u co-promot region
glpg option co-promot uk germani franc itali spain belgium
netherland luxembourg profit would split equal
exhibit filgotinib term glpg
glpg co-fund global develop activ
gilead respons
gilead respons
countri co-promot option
netherland luxembourg glpg opt
uk germani franc itali spain belgium
develop regulatori commer mileston
owe
last three book sale countri
tier start region outsid co-
promot includ us
immunolog drug compani studi filgotinib jak
inhibitor shown efficaci
program underway ra crohn diseas cd ulcer coliti uc
recent posit data updat ankylos spondyl psoriat arthriti
exhibit indic develop filgotinibsourc galapago present septemb
ra phase studi first catalyst emerg finch come end
expect data finch biolog inadequ respond
base case major credit assign ra uc cd
recent proof-of-concept achiev studi
exhibit late stage studi filgotinibsourc gilead present safeti key consider jak inhibitor rang platelet infect
issu
jak inhibitor affect neutrophil lymphocyt natur kill cell chang vari
platelet level focu recent
filgotinib saw lower testosteron level two speci preclin
clinic find
exhibit safeti profil jak inhibitor catalyst filgotinib includ studi safeti studi potenti cover
upadacitinib also oral develop expect file
therapi could fda panel might learn agenc view
toler profil
also wait filgotinib safeti studi male ulcer coliti call
manta measur testicular safeti men studi still enrol may take
anoth month read estim
conserv around launch year filgotinib believ big
unadjust sale indic
model launch sinc compani file without ulcer coliti safeti
studi men
project could read current underway
exhibit filgotinib sale indic cantor cantor colitisoth indictionsexhibit filgotinib sale cantor vs consensu cantor fitzgerald cantorfilgotinib- consensu line consensu start think potenti liso-cel
competit
line consensu
slightli consensu specif broken third line later sale
analysi assum consensu
exhibit yescarta sale cantor vs consensu factset cantor cantoryescarta consensu physician check note manufactur challeng kymriah
novarti nv cover current market kymriah
one check describ manufactur failur one patient
patient success retreat yescarta
believ issu specif dlbcl
also discuss novarti call prepar remark
model slightli total car-t revenu annual basi
major sale come dlbcl
prior work shift timelin bit studi beyond dlbcl
ad sale bcma multipl myeloma think car-t product
may similar differ
exhibit cart revenu indication- cantor estimatessourc cantor fitzgerald market dlbcl myeloma besid acquir kite gilead build expertis cell therapi
gilead also made invest mani compani space well
exhibit compani gilead partner cell therapi
subsidiari cell engin
synnotch dual antigen recognit cart
throttl small molecul modul cart
patient specif cell therapi oncolog
hiv hbv therapeut
collabor next-gen ex-vivo oncolog
collabor id understand
immunolog basi ra ibd lupu
cooper agreement patient-
collabor licens agreement
gamma delta tcr tech solid tumor
john milligan phd dr milligan join appoint chief execut offic march began
career gilead research scientist subsequ held leadership posit project manag corpor develop
name chief offic appoint chief oper offic presid
john mchutchison ao md dr mchutchison join gilead appoint chief scientif offic march prior
join gilead dr mchutchison work duke univers medic center serv associ director duke clinic
research institut also held posit professor medicin divis gastroenterolog duke univers medic
center associ director duke clinic research institut co-director duke clinic translat scienc award prior
posit duke dr mchutchison spent nearli year scripp clinic recent medic director liver transplant
also previous held assist professorship medicin univers southern california
robin washington ms washington join gilead senior vice presid chief offic overse
global financ inform technolog organ ms washington promot execut vice presid ms
washington previous chief offic hyperion solut acquir oracl corpor march prior
ms washington serv number execut posit peoplesoft recent role senior vice presid
gregg alton mr alton join serv gener counsel current role mr alton
respons commerci access oper africa asia europ latin america middl east govern affair polici
public affair prior join gilead mr alton attorney law firm cooley godward llp special merger
acquisit corpor partnership corpor financ transact healthcar inform technolog compani
cantor fitzgerald research million except ep
cantor biotech gilead incom statementalethia million except product sale nash car-t contract expensescog product non- product non- product opex non- growth incom non- oper oper itemsinterest incom pre-tax profit incom effect tax rate incom gilead non- incom incom non-control loss non-control ep ep growth ep ep ep dilut dilut gilead incom statement- quarterli
cantor fitzgerald research million except ep
incom product sale nash car-t contract salestot expensescog product non- product non- product opex non- growth incom non- oper oper itemsinterest incom profit incom effect tax rate incom gilead non- incom incom non-control loss non-control ep ep growth ep ep ep dilut dilut septemb
cantor biotech gilead scienc balanc sheet million except ep alethia term receiv tax tax prepaid current current market portion prepaid defer tax plant equip asset long term current portion long-term debt oblig account accru defer current current debt defer tax long term compon current redeem convert liabil septemb
cantor biotech gilead scienc statement million except ep alethia operationsnet non-oper account expens investingcapit expenditur net cash sale matur market market financingdebt ce short term septemb
gilead global biopharmaceut compani major base busi revenu base infecti diseas pipelin
evolv inflamm oncolog nash compani headquart foster citi california
